Press Release: Bulgarian Cystic Fibrosis Patient Joins International Campaign Standing up for the Rights of Patients to Access Essential Medicines

Bulgarian cystic fibrosis patient joins international campaign standing up for the rights of patients to access essential medicines Rositsa Malinova, a 22-year-old resident of Pazardzhik, Bulgaria, is taking on the…

Continue Reading Press Release: Bulgarian Cystic Fibrosis Patient Joins International Campaign Standing up for the Rights of Patients to Access Essential Medicines

Transitioning from Pediatric to Adult Care with Cystic Fibrosis Needs to be a Team Effort

Transitions to adult care for patients who have a chronic respiratory disease, like cystic fibrosis, or a type of neuromuscular disease that influences the respiratory system is something that the medical…

Continue Reading Transitioning from Pediatric to Adult Care with Cystic Fibrosis Needs to be a Team Effort
Cystic Fibrosis Patients May Now Be Able to Have Hearing Loss Screenings Done Via Tablets
source: pixabay.com

Cystic Fibrosis Patients May Now Be Able to Have Hearing Loss Screenings Done Via Tablets

by Danielle Bradshaw from In The Cloud Copy A recently performed study has demonstrated that it is possible to use tablets to screen patients that have chronic lung conditions -…

Continue Reading Cystic Fibrosis Patients May Now Be Able to Have Hearing Loss Screenings Done Via Tablets
Two Poster Presentations on ELX-02 for Cystic Fibrosis Appeared at the NACFC
karmasprenger / Pixabay

Two Poster Presentations on ELX-02 for Cystic Fibrosis Appeared at the NACFC

In late September and early October, the North American Cystic Fibrosis Conference (NACFC) went virtual, as many conferences and symposia this year have been forced to do. However, that does…

Continue Reading Two Poster Presentations on ELX-02 for Cystic Fibrosis Appeared at the NACFC
Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials
source: pixabay.com

Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials

According to a story from BioSpace, the US Food and Drug Administration (FDA) recently announced that it has awarded grant funding that will go towards six clinical trials that will…

Continue Reading Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials
The FDA Has Provided 16 Million Dollars to Scientists to Continue Rare Disease Research During the Pandemic
source: pixabay.com

The FDA Has Provided 16 Million Dollars to Scientists to Continue Rare Disease Research During the Pandemic

 The United States FDA has just announced that they will be providing  6 new grants, which are worth 16 million dollars for rare disease research. These grants will last a…

Continue Reading The FDA Has Provided 16 Million Dollars to Scientists to Continue Rare Disease Research During the Pandemic
Vertex Will Present Data on CFTR Modulators as Treatments for Cystic Fibrosis
source: pixabay.com

Vertex Will Present Data on CFTR Modulators as Treatments for Cystic Fibrosis

Vertex Pharmaceuticals will present data on the long-term use of their cystic fibrosis (CF) treatments at the 43rd European Cystic Fibrosis Digital Conference, and then again at the 2020 North…

Continue Reading Vertex Will Present Data on CFTR Modulators as Treatments for Cystic Fibrosis
KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis
1041483 / Pixabay

KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis

  On September 25, biotechnology company Vertex Pharmaceuticals Incorporated ("Vertex") announced FDA-approval of KALYDECO (ivacaftor) for pediatric patients with cystic fibrosis (CF). Specifically, KALYDECO can treat infants between 4-6 months…

Continue Reading KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis
Experimental Treatment for Cystic Fibrosis Lung Infections gets Updated Trial Design
source: pixabay.com

Experimental Treatment for Cystic Fibrosis Lung Infections gets Updated Trial Design

According to a story from BioSpace, the biopharmaceutical company Aridis Pharmaceuticals, Inc., has recently announced that it has struck an agreement with the US Food and Drug Administration (FDA) in…

Continue Reading Experimental Treatment for Cystic Fibrosis Lung Infections gets Updated Trial Design
Cystic Fibrosis Foundation and ContraFect Enter Agreement to Develop CF Treatment
source: pixabay.com

Cystic Fibrosis Foundation and ContraFect Enter Agreement to Develop CF Treatment

The biotechnology company ContraFect has entered into an agreement with the Cystic Fibrosis Foundation. This funding agreement aims to investigate and develop direct lytic agents (DLAs) as a treatment for…

Continue Reading Cystic Fibrosis Foundation and ContraFect Enter Agreement to Develop CF Treatment